Patents Issued in October 3, 2017
  • Patent number: 9775861
    Abstract: An ophthalmic composition of water soluble ingredients provides additional moisture to the eye by promoting moisture absorption from the air and providing long lasting relief. The composition can include two groups of ingredients, one a liquid and the other a solid. Together, the ingredients form a substance that ranges from a liquid to a gel. Benefits of such composition include longer lasting symptom relief with less applications and increased moisture production.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: October 3, 2017
    Inventors: Paul S. Jensen, Isaiah U. Lieberman
  • Patent number: 9775862
    Abstract: A method of enhancing the binding of growth factors and cell cultures to a demineralized allograft bone material which includes applying ex vivo an effective quantity of an ionic force change agent to at least a portion of the surface of a demineralized allograft bone material to produce a binding-sensitized demineralized allograft bone material and implanting the binding-sensitized demineralized allograft bone material into a host bone. The ionic force change agent may include at least one of enzymes, pressure, chemicals, heat, sheer force, oxygen plasma, supercritical nitrogen, supercritical carbon, supercritical water or a combination thereof. A molecule, a cell culture, or a combination thereof is administered to the binding-sensitized demineralized allograft bone material.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: October 3, 2017
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Guobao Wei, Susan J. Drapeau
  • Patent number: 9775863
    Abstract: A method of treating liver-based inborn, metabolic deficiencies is disclosed by treatment of an individual, such as a patient suffering from liver-based inborn, metabolic deficiencies, with human progenitor or stem cells, a cell population or their progeny. The cells used in the treatment have the following characteristics. They are positive for vimentin, ?-smooth muscle actin (ASMA), and for at least one mesenchymal marker such as CD90, CD29, CD73, and CD44. They are positive for at least one hepatocyte marker such as albumin, alpha-fetoprotein, alpha-1 antitrypsin, HNF-4 and MRP2 transporter. They express at least one hepatocyte-like property or function such as G6P, CYP1B1, CYP3A4, TDO, TAT, GS, GGT, CK8, and EAAT2. They are negative for at least one marker such as cytokeratin-19, CD45, CD34, CD49f, CD133, HLA-DR, and CD117. They have mesenchymal-like morphology. They originate from human adult liver cells.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: October 3, 2017
    Assignee: UNIVERSITÉ CATHOLIQUE DE LOUVAIN
    Inventors: Etienne Sokal, Mustapha Najimi
  • Patent number: 9775864
    Abstract: The invention provides methods for the treatment of vaginal laxity which include delivering a cell-containing composition to the vagina. The composition can include fat tissue to provide a bulking effect to reduce the size of the vaginal opening. The cells can provide healing and revascularization of the vaginal treatment area to sustain the bulking provided by the fat. The invention also provides systems and compositions useful for performing the method, and can include instruments and devices for removal of autologous adipose tissue from a patient (e.g., by liposuction), equipment for the enrichment of cells from adipose tissue, mechanical processing of adipose tissue, and the mixing of cells and processed adipose tissue. Devices for the delivery of the cell compositions to the vagina can also be included in the system.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: October 3, 2017
    Inventor: David J. Yonce
  • Patent number: 9775865
    Abstract: Systems, kits and methods are provided, which analyze the large intestine content and utilize acoustic signals detected during delivery of water into the large intestine and drained large intestine contents to derive large intestine characteristics such as microbiotal analysis. Systems may include a water delivery unit including a water supply and a nozzle connected thereto, configured to introduce water controllably into a patient's large intestine, and an analysis unit that provides information about the drained contents using optical examination or biological assays. The information may be related to acoustic analysis of signals from acoustic sensors that are attachable to a patient's abdomen. A variety of sensor configurations, positioning options, analysis strategies and large intestine characteristics are presented.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: October 3, 2017
    Assignee: HYGIEACARE, Inc.
    Inventors: Gavriel David Meron, Mordechai Yehuda Frisch
  • Patent number: 9775866
    Abstract: Microcapsules are described that comprise (a) a liquid aqueous or hydrogel core; (b) a semipermeable membrane surrounding said core; (c) live animal cells (e.g., pancreatic cells) in the core; and (d) oxygen-generating particles in said core, said oxygen-generating particles included in said microcapsules in an amount sufficient to lengthen the duration of viability of said animal cells in said microcapsules. Compositions comprising such microcapsules and uses thereof, such as in treating diabetes, are also described.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: October 3, 2017
    Assignee: Wake Forest University Health Sciences
    Inventors: Emmanuel C. Opara, Benjamin S. Harrison
  • Patent number: 9775867
    Abstract: There is provided an isolated E. coli strain deposited at the International Depositary Authority of Canada (IDAC) on Jun. 20, 2013 and attributed accession number 200613-01. There is also provided methods of using this strain for preventing edema disease or diarrhea caused by an F18 pathogenic E. coli infection in an animal.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: October 3, 2017
    Assignee: PREVTEC MICROBIA INC.
    Inventors: John Morris Fairbrother, Éric Nadeau, Clarisse Desautels
  • Patent number: 9775868
    Abstract: The present invention relates to a traditional Chinese medicine composition for regulating immunity and preparation method thereof, characterized in that the composition comprises raw materials such as Radix Panacis Quinquefolii, Ganoderma, fermented Cordyceps sinensis powder, Flos Rosae Rugosae, and Rhizoma Anemarrhenae and is prepared into various conventional pharmaceutical formulations through processes such as pulverization, water decoction and alcohol extraction. The traditional Chinese medicine composition is effective in preventing and treating allergic diseases, hepatitis B and AIDS, elevating leukocytes, preventing and treating radiation injury, reducing toxic and side effects resulting from radiotherapy and chemotherapy, improving the male sexual function, enhancing immunity of the human body and alleviating physical fatigue.
    Type: Grant
    Filed: September 22, 2013
    Date of Patent: October 3, 2017
    Assignee: JIANGZHONG PHARMACEUTICAL CO., LTD.
    Inventors: Hongguang Zhong, Minzhi Yi, Jianzhong Lu
  • Patent number: 9775869
    Abstract: A composition having an extract of seed of Emblica officinalis. Methods of preparing extract of seed of Emblica officinalis. An amla seed blend composition having various ratios of extracts of seeds of Emblica officinalis. Nutraceutical or pharmaceutical methods for decreasing the total cholesterol, decreasing triglyceride, decreasing blood glucose level, enhancing HDL-C levels, increasing the HDL-C level to total cholesterol ratio, lowering LDL-C levels, decreasing the CRP level, decreasing the intima media thickening, reducing hair fall in mammals especially human beings. The extract of seed of Emblica officinalis, or the amla seed blend composition is more effective compared to extracts prepared from fruits of Emblica officinalis.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: October 3, 2017
    Inventor: Benny Antony
  • Patent number: 9775870
    Abstract: The present invention relates to an extract of a processed herbal medicinal plant and a composition for skin external application which contains the extract. More specifically, the composition for skin external application contains an extract of processed herbal medicinal plant, prepared through a method comprising the steps of: (a) processing an herbal medicinal plant by a process of boiling, steaming, roasting, baking or heating the medicinal plant or a combination of two or more of these processes; (b) obtaining an extract of the processed medicinal plant. The composition shows an improved antioxidant effect.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: October 3, 2017
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Jun Seong Park, Hye Yoon Park, Dong Hyun Kim, Eun Jeong Moon, Ji Hye Chung, Jae Kyoung Lee, Duck Hee Kim, Han Kon Kim
  • Patent number: 9775871
    Abstract: Herbal compositions and their use in the prevention and/or treatment of hepatitis are provided The herbal compositions comprise an extract of flowers, leaves, and roots from the plant genera Cordia, Annona, and Curcuma, respectively, wherein the specific species are Cordia lutea, Annona muricata and Curcuma longa.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: October 3, 2017
    Assignees: SABELL CORPORATION
    Inventor: Jose Gonzalo Cabanillas Coral
  • Patent number: 9775872
    Abstract: The present disclosure refers to topical pharmaceutical bases that possess antiviral properties. Further, these topical pharmaceutical bases are employed for preventing a patient to be infected by viral diseases. The topical pharmaceutical bases include Amazonian oils and resins, such as pracaxi oil and breu-branco resin. The synergistic effect of pracaxi oil combined with breu-branco resin results in a highly effective antiviral treatment. Suitable active pharmaceutical ingredients (APIs) can be incorporated to the topical pharmaceutical bases to formulate topical pharmaceutical compositions, which improve antiviral effects. The synergistic effect provided by the combination of pracaxi oil and breu-branco resin enables lower dosage requirements of the associated APIs when topical pharmaceutical compositions are employed for preventing viral diseases.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: October 3, 2017
    Assignee: Professional Compounding Centers of America
    Inventor: Daniel Banov
  • Patent number: 9775873
    Abstract: The present disclosure relates to compositions and related methods to reduce body weight, body fat, waist and hip size, plasma total cholesterol, LDL, triglycerides, blood glucose, leptin and C-reactive protein levels and increase in HDL and serotonin levels in an mammal. The LeptiCore® formulation disclosed, at both the low and high dosages, is helpful in the management of fat gain and its related complications. The higher dosage resulted in significantly greater reductions in body weight and triglyceride, blood glucose, and C-reactive protein levels, as well as increased serotonin levels.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: October 3, 2017
    Inventor: Julius Enyoug Oben
  • Patent number: 9775874
    Abstract: In a new supplemental combination and method of treatment, the herbs Vitex agnus-castus (chasteberry), green tea, and arginine treat premenstrual syndrome, premenstrual tension, as an alternative to conventional women's hormone replacement therapy, and to offset the problems related to sub-optimal hormone balance or decline resulting from age, genetics, stress, or environmental influences. Furthermore, the combination may be enhanced with a phytoestrogen and/or a progesterone-receptor enhancing agent.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: October 3, 2017
    Assignee: The Daily Wellness Company
    Inventor: Denny W. Kwock
  • Patent number: 9775875
    Abstract: The invention discloses a method of processing Zingiber zerumbet for producing a processed sample of Zingiber zerumbet, which easily releases flavonoids in a following extraction process. The method includes the steps of: soaking a raw sample of Zingiber zerumbet with a processing reagent selected from rice vinegar or yellow wine at 23-27° C. for 20-28 hours; and steaming the soaked product at 0.6-1.4 kg/cm2, 80-120° C. for 20-40 minutes.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: October 3, 2017
    Assignee: HAN SHENG PHARMTECH, INC.
    Inventors: Shorong-Shii Liou, I-Min Liu, Cheng Yang, Sheng-Da Lin, Chi-Da Fang, Bo-Wei Lin, Wan-Ling Huang, Ya-Ting Shiu
  • Patent number: 9775876
    Abstract: Embodiments herein generally relate to methods, compositions and uses of CaMKII inhibitors. Other embodiments relate to methods, compositions and uses of agents that target CaMKII. Yet further embodiments relate to compositions, methods and uses of CaMKIIN-derived molecules and other CaMKII inhibitor molecules that inhibit autonomous CaMKII activity. In accordance with these embodiments, compositions that inhibit autonomous CaMKII activity may be used for treating conditions causing neuronal cell death, for treating cancer or for treating neurodegenerative disorders.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: October 3, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporate
    Inventors: K. Ulrich Bayer, Steve Coultrap
  • Patent number: 9775877
    Abstract: A novel combination comprising a ?-hairpin peptidomimetic of the formula cyclo(-Thr-Trp-Ile-Dab-Orn-DDab-Dab-Trp-Dab-Dab-Ala-Ser-DPro-Pro) (I), and a compound of the glycylcycline class, especially tigecycline, that enable therapeutic control of specific bacterial infections in human or animals at doses of the individual compounds lower than either of the compounds administered alone. The combination can be used as a medicament to treat e.g. skin or soft tissue infections; eye, ear, blood stream, or intra-abdominal infections; infections related to respiratory diseases, to bone diseases, to cardiovascular diseases, to genitourinal diseases, or to gastrointestinal diseases.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: October 3, 2017
    Assignee: POLYPHOR AG
    Inventors: Glenn E. Dale, Daniel Obrecht, Francesca Bernardini
  • Patent number: 9775878
    Abstract: Methods of treating bacterial infections in a subject using a synergistic combination of oritavancin and a polymyxin are disclosed.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: October 3, 2017
    Assignee: THE MEDICINES COMPANY
    Inventors: Gregory Moeck, Francis Arhin
  • Patent number: 9775879
    Abstract: The present invention relates to a use of a human small leucine zipper protein in the adipocyte differentiation procedure. More specifically, sLZIP binds with PPAR?2 to induce the formation of a complex of HDAC3 and PPAR?2, thereby functioning as a corepressor to negatively inhibit the transcriptional activity of PPAR?2 and suppress the differentiation to adipocytes, and thus can be used as a marker for treating diabetes and obesity and developing new medicines therefor.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: October 3, 2017
    Assignee: Korea University Research and Business Foundation
    Inventors: Je Sang Ko, Jeong-Han Kim
  • Patent number: 9775880
    Abstract: The present invention relates to a composition which comprises the following myelin basic protein peptides: MBP 30-44; MBP 83-99; MBP 131-145; and MBP 140-154. The composition may be used to treat a disease, in particular multiple sclerosis and/or optical neuritis and the invention also relates to such uses and methods.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: October 3, 2017
    Assignee: APITOPE TECHNOLOGY (BRISTOL) LIMITED
    Inventors: David Wraith, Heather Streeter
  • Patent number: 9775881
    Abstract: Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule are provided. Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule and at least one anti-angiogenic agent are provided.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: October 3, 2017
    Assignees: Five Prime Therapeutics, Inc., GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: David Bellovin, Kevin Baker, Thomas Brennan, Arundathy Nirmalini Pandite, Bijoyesh Mookerjee, Maurice P. DeYoung, Rakesh Kumar
  • Patent number: 9775882
    Abstract: Medical devices and methods including polymers having biologically active agents therein are disclosed. The medical devices can be useful as implantable devices such as orthopedic implants.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: October 3, 2017
    Assignee: Medtronic, Inc.
    Inventors: Phillip Edward McDonald, Christopher M. Hobot
  • Patent number: 9775883
    Abstract: Without limitation, some embodiments comprise a method of treatment for promoting recovery of peripheral neuropathy in a subject, including administering to a subject in need of such treatment a therapeutically effective amount of a composition comprised of thymosin beta 4, amino acid sequences LKKTET or LKKTNT, and/or any conservative variants thereof, or an agent that stimulates production of any of those materials, or a conservative variant thereof.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: October 3, 2017
    Assignee: Henry Ford Health System
    Inventors: Michael Chopp, Zhenggang Zhang, Daniel C. Morris, Lei Wang
  • Patent number: 9775884
    Abstract: A fibrinogen preparation is provided which has an improved solubility, may be prepared within a short time and may be used rapidly in clinical set-up. A solid fibrinogen preparation comprising as a main ingredient fibrinogen and further containing the following components: albumin; a nonionic surfactant; a basic amino acid or a salt thereof; and at least two amino acids or a salt thereof selected from an acidic amino acid or a salt thereof and a neutral amino acid or a salt thereof. The solid fibrinogen composition of the present invention may be held on a medical material to form a supporting material holding fibrinogen. Besides, the supporting material holding fibrinogen may be combined with a component comprising as a main ingredient thrombin to provide a fibrin adhesive.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: October 3, 2017
    Assignee: The Chemo-Sero-Therapeutic Research Institute
    Inventors: Shinichi Miyagawa, Tatsuya Araki, Tsutomu Hamuro, Mika Okuda, Hiroshi Kaetsu
  • Patent number: 9775885
    Abstract: The present invention relates to a method for treating a bone loss disease, condition, or disorder in a subject in need thereof, comprising administering to said subject a pharmaceutically effective amount of a composition comprising thrombomodulin lectin-like domain (TMD1).
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: October 3, 2017
    Assignee: KAOHSIUNG MEDICAL UNIVERISTY
    Inventors: Tsung-Lin Cheng, Jwu-Lai Yeh, Mei-Ling Ho, Guey-Yueh Shi, Hua-Lin Wu
  • Patent number: 9775886
    Abstract: The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.
    Type: Grant
    Filed: September 11, 2012
    Date of Patent: October 3, 2017
    Assignee: Celularity, Inc.
    Inventors: Mohit Bhatia, Chris Lugo, Qian Ye, James W. Edinger
  • Patent number: 9775887
    Abstract: Disclosed is a formulation of the following enzymes: Beta Glucanase, Chymotrypsin, Phytase, Lactase, and Invertase, which has been found to be effective in treating salicylate intolerant people, and causing a significant improvement in a wide variety of pathologies and symptoms, including, but not limited to: stuttering, migraines, ADHD, behavioral deficits, Tourettes disease, seizures, autism (ASD), atrial fibrillation, anxiety, depression, joint pain, cognitive and perceptual disorders, respiratory difficulties and non-diabetic neuropathy.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: October 3, 2017
    Inventor: Thea Fournier
  • Patent number: 9775888
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: October 3, 2017
    Assignee: ALBUMEDIX A/S
    Inventors: David J. Ballance, Darrell Sleep
  • Patent number: 9775889
    Abstract: Methods and combinations are provided for controlling the duration of action, in vivo, of matrix-degrading enzymes. The methods and combinations permit temporary in-vivo activation of matrix-degrading enzymes upon administration to the extra cellular matrix (or “ECM”). Matrix-degrading enzymes having a controlled duration of action can be used to treat ECM-mediated diseases or disorders characterized by increased deposition or accumulation of one or more ECM components.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: October 3, 2017
    Assignee: Halozyme, Inc.
    Inventors: Gilbert Keller, Gregory I. Frost
  • Patent number: 9775890
    Abstract: The present invention relates to compositions and methods for cell transplantation. In particular, the present invention provides a composition comprising procoagulant cells and at least one factor Xa inhibitor, preferably rivaroxaban, as well as at least one thrombin inhibitor, preferably bivalirudin.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: October 3, 2017
    Assignee: UNIVERSITÉ CATHOLIQUE DE LOUVAIN
    Inventors: Xavier Stephenne, Etienne Sokal, Mustapha Najimi, Stéphane Eeckhoudt, Cédric Hermans
  • Patent number: 9775891
    Abstract: The present invention relates to methods of inducing a T-cell response against a EGFRvIII in a subject. These method comprise administering to a subject a composition which expresses at least one immunogenic polypeptide, the amino acid sequence of which comprise a plurality of EGFRvIII polypeptide sequences, the sequence of which each comprise EEKKGNYV (SEQ ID NO: 3), and/or administering the polypeptide itself.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: October 3, 2017
    Assignees: ADURO BIOTECH, INC., PROVIDENCE HEALTH & SERVICES—OREGON
    Inventors: Peter M. Lauer, Keith Bahjat
  • Patent number: 9775892
    Abstract: There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the RAS protein. Each of the first and second peptides comprises a region of at least 8 amino acids which includes position 13 of the RAS protein. Each of said regions of the first and second peptides independently has at least 6 amino acid residues, other than at said position 13, which are identical to the corresponding region of the RAS protein. Each of the first and the second peptides has a point mutation at the amino acid corresponding to said position 13. The point mutation of the first peptide is different from the point mutation of the second peptide.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: October 3, 2017
    Assignee: TARGOVAX ASA
    Inventor: Jon Amund Eriksen
  • Patent number: 9775893
    Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: October 3, 2017
    Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jiunn-Horng Lin, Jyh-Perng Wang, Ming-Wei Hsieh, Zeng-Weng Chen, Chien-Yu Fang, Hsueh-Tao Liu, Ping-Cheng Yang
  • Patent number: 9775894
    Abstract: Compositions and methods are provided that enable activation of innate immune responses through RIG-I like receptor signaling. The compositions and methods incorporate synthetic nucleic acid pathogen associated molecular patterns (PAMPs) that comprise elements initially characterized in, and derived from, the hepatitis C virus genome.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: October 3, 2017
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Michael J. Gale, Jr., Gretja Schnell, Yueh-Ming Loo
  • Patent number: 9775895
    Abstract: HIV neutralizing peptides, sulfated HIV-1 envelope proteins and immunogenic fragments thereof are disclosed, as well as nucleic acids encoding these molecules and methods of producing these peptides, envelope proteins and fragments. Methods are also provided for the treatment or prevention of a human immunodeficiency type 1 (HIV-1 ) infection. The methods can include administering to a subject an HIV neutralizing peptide, sulfated HIV-1 envelope protein or immunogenic fragment thereof as disclosed herein. In several embodiments, administering the HIV neutralizing peptide, sulfated HIV-1 envelope protein or immunogenic fragment generates an immune response in a subject.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: October 3, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Paolo Lusso, Raffaello Cimbro
  • Patent number: 9775896
    Abstract: The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: October 3, 2017
    Assignee: Qu Biologics Inc.
    Inventor: Harold David Gunn
  • Patent number: 9775897
    Abstract: Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: October 3, 2017
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Yosef Refaeli, Brian Curtis Turner
  • Patent number: 9775898
    Abstract: Vaccine compositions for use in inducing enhanced antigen-specific T cell-mediated immune responses in a subject in need thereof are disclosed. The composition comprises (a) a therapeutically effective amount of an immunogenic protein comprising at least an antigen of a pathogen; (b) a saponin-base adjuvant selected from the group consisting of GPI-0100, Quil A, QS-21; and (c) a Toll-like receptor (TLR) agonist adjuvant selected from the group consisting of monophosphoryl lipid A (MPL), and CpG1826.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: October 3, 2017
    Assignee: TheVax Genetics Vaccine Co., Ltd.
    Inventors: Chia-Mao Wu, Jiun-Ming Wu, Yi-Tsui Chiu, Yin-Ching Lin, Hsien-Kai Chuang, Fu-Tan Hsieh, Kuan-Ming Chen
  • Patent number: 9775899
    Abstract: Methods of treating neuronal disorders, such as mechanical neuronal traumas and neurodegenerative disorders, with TWEAK or a TWEAK receptor blocking agents are presented.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: October 3, 2017
    Assignee: Biogen MA Inc.
    Inventors: Linda C. Burkly, Kyungmin Hahm, Timothy Zheng, Steve Perrin, John Lincecum
  • Patent number: 9775900
    Abstract: In the early detection of cancer, in particular bladder cancer, a photodynamic diagnosis uses, as a photosensitizer, a formulation that contains sodium hypericinate that is bonded to polyvinylpyrrolidone or complexed with polyvinylpyrrolidone.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: October 3, 2017
    Assignee: SANOCHEMIA PHARMAZEUTIKA AG
    Inventors: Stefan Welzig, Beate Kälz, József Gungl, Klaus Gerdes, Werner Frantsits, Christina Abrahamsberg
  • Patent number: 9775901
    Abstract: Materials capable of delivering stabilized free radicals to targeted treatment sites. The materials comprise semi-crystalline, hydrolytically degradable polymers that are subjected to ionizing radiation to create stabilized free radicals therein. Upon exposure to oxygen containing aqueous media, the materials generate reactive oxidative species which are useful in biological processes.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: October 3, 2017
    Assignee: W.L. Gore & Associates, Inc.
    Inventors: Tiffany J. Brown, Adam S. Lafleur, Kenneth Mazich, Jeffrey C. Towler, Ji Zhang
  • Patent number: 9775902
    Abstract: The present invention relates to methods and agents useful for the treatment of stroke, including ischemic stroke and hemorrhagic stroke. In particular, methods and agents for treating stroke in a subject are provided, wherein the agent is administered prior to diagnosis of the stroke as an ischemic stroke or a hemorrhagic stroke.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: October 3, 2017
    Assignee: FIBROGEN, INC
    Inventors: Stephen J. Klaus, Ingrid Langsetmo Parobok, Christopher T. Jacob
  • Patent number: 9775903
    Abstract: This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: October 3, 2017
    Assignees: JOHNS HOPKINS UNIVERSITY, OPKO IRELAND GLOBAL HOLDINGS, LTD.
    Inventors: Gary H. Posner, Lindsey C. Hess, Alvin S. Kalinda, Rachel D. Slack, Uttam Saha, P. Martin Petkovich
  • Patent number: 9775904
    Abstract: The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: October 3, 2017
    Assignee: SANOFI
    Inventors: Martin Bossart, Ralf Elvert, Andreas Evers, Torsten Haack, Siegfried Stengelin, Michael Wagner
  • Patent number: 9775905
    Abstract: An intrauterine device having at least one first pharmaceutically active ingredient and at least one first layer made of at least a first polymeric material, wherein between about 10 and about 60 v/v % of at least one particulate material is dispersed and/or incorporated in the first polymeric material. The presence of the particulate material will reduce the porosity of the polymer or otherwise obstruct the diffusion of the pharmaceutically active ingredient being released, thereby slowing its rate of release. In this way, it is possible to regulate the release rate and/or initial burst of the device, simply by adjusting the amount of particles/particulate material in the first layer, instead of having to adapt the size of the device to the desired release pattern, which requires expensive changes in production equipment and manufacturing processes.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: October 3, 2017
    Assignee: QPharma AB
    Inventor: John Ingvar Feldtblad Kendrup
  • Patent number: 9775906
    Abstract: Some aspects of this disclosure relate to a method of treating an opthalmic disease affecting an eye of a patient comprising forming a covalently-crosslinked hydrogel in situ at a peri-ocular, intra-ocular, or intra-vitreal site for controlled release of a therapeutic agent.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: October 3, 2017
    Assignee: Incept LLC
    Inventors: Amarpreet S. Sawhney, William H. Ransone, II
  • Patent number: 9775907
    Abstract: Unpurified or low pure soy phosphatidylserine is used to make cochleates. The cochleates contain about 40-74% soy phosphatidylserine, a multivalent cation and a biological active. A preferred cochleate contains the antifungal agent amphotericin B.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: October 3, 2017
    Assignee: MATINAS BIOPHARMA NANOTECHNOLOGIES, INC.
    Inventors: Raphael Mannino, Ruying Lu
  • Patent number: 9775908
    Abstract: The subject of the present invention is a transdermal preparation containing pharmaceutically active ingredient, wherein the particles of the active ingredient are coated with highly volatile silicones or a mixture thereof, and these coated particles are dispersed in a gel or cream base. The volatile silicone component is hexamethyldisiloxane and/or octamethyltrisiloxane and/or decamethylpentacyclo-siloxane. A further subject of the present invention is a method for the preparation of such pharmaceutical compositions.
    Type: Grant
    Filed: July 10, 2008
    Date of Patent: October 3, 2017
    Assignee: EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG
    Inventors: Endre Mikulásik, Patrik Fazekas
  • Patent number: 9775909
    Abstract: The viscosity of aqueous dispersions of normally solid organic peroxides may be advantageously lowered through the use of surfactants which are polyglyceryl esters of C6-C12 fatty acids. The reduction in viscosity facilitates milling the peroxides to reduce particle size and also provides dispersions of small particle size peroxides which may be readily poured or pumped.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: October 3, 2017
    Assignee: Arkema Inc.
    Inventors: Thomas H. Kozel, Joseph M. Gravelle, Timothy Belford, Tomas Salvador
  • Patent number: 9775910
    Abstract: An aqueous suspension of a hydrophobic nutrient is disclosed. In particular, the nutrient, in ester form, is combined with a selected dispersion aid and a dispersion agent(s), and then dispersed in an aqueous medium to form the suspension.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: October 3, 2017
    Assignee: Ingredient Innovations International
    Inventors: Christopher J Milley, Scott E Peters